Literature DB >> 6992228

Effects of intravenous infusion of prostacyclin (PGI2) in man.

J O'Grady, S Warrington, M J Moti, S Bunting, R Flower, A S Fowle, E A Higgs, S Moncada.   

Abstract

Prostacyclin infused intravenously in human volunteers induces ex vivo inhibition of platelet aggregation, tachycardia and hypotension. The inhibition of platelet aggregation is obtained with slightly lower doses than those which exhibit cardiovascular effects. The cardiovascular effects disappeared within a few minutes after discontinuing the infusion of prostacyclin but the platelet effects were longer lasting. Prostacyclin did not have any effect on platelet count, platelet factor 3, accelerated partial thromboplastin time, prothrombin time, euglobulin clot lysis time, fibrinogen degradation products, blood glucose concentration or urine sodium potassium ratio.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6992228     DOI： 10.1016/0090-6980(80)90030-1

Source DB:  PubMed          Journal:  Prostaglandins        ISSN： 0090-6980


  19 in total

1.  No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial.

Authors:  Albertus J Kooter; Richard G Ijzerman; Otto Kamp; Anco B Boonstra; Yvo M Smulders
Journal:  BMC Pulm Med       Date:  2010-03-30       Impact factor: 3.317

Review 2.  Prostacyclin in the intensive care setting.

Authors:  D Dunbar Ivy
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

3.  Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.

Authors:  Priska Kaufmann; Noémie Hurst; Béatrice Astruc; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2016-11-24       Impact factor: 2.953

Review 4.  Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

5.  The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey.

Authors:  G Allan; M J Follenfant; P Lidbury; P L Oliver; B J Whittle
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

6.  Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Authors:  H Pickles; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

7.  Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction.

Authors:  F J Kiernan; J Kluger; J C Regnier; M Rutkowski; A Fieldman
Journal:  Br Heart J       Date:  1986-11

8.  A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.

Authors:  J O'Grady; A Hedges; B J Whittle; L A Al-Sinawi; Q A Mekki; C Burke; S G Moody; M J Moti; S Hassan
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

9.  Effect of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients.

Authors:  M Kuźniewski; W Sułowicz; J Lisiewicz
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

10.  The role of expansion, of prostaglandins and catecholamines in the development of acute renal failure.

Authors:  N Papanicolaou; G Skoutelis; P Papanicolaou; P Theodorakopoulos; M Paris; A Dontas; J Bariety; P Milliez
Journal:  Experientia       Date:  1982-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.